Any current/future new fundraising through debt or equity?

The company received INR 277.5 crores from a preferential issue in July 2025, of which INR 175 crores has already been used to repay term debt. Currently, the company is long-term net debt free on a net term debt basis. Debt-to-EBITDA ratio is less than 2, with management targeting to keep it below 2, aiming for around 1.5 or less. Working capital utilization is expected to improve, with inventory rationalization and no major capex planned, which should help reduce debt further. No explicit mention of new fundraising through debt or equity during the call beyond the preferential issue

Any current/future capex/capital investment/strategic investment?

All planned capex projects have been completed, with plants commissioned and fully operational. Two new plants have been commercialized, and trial runs are ongoing in one additional plant. No major capex is planned or necessitated in the near term. The company is focusing on leveraging existing manufacturing capacities to ramp up new molecule launches and orders. Emphasis is on optimizing working capital rather than incurring significant new capital investments in FY '26.

Future growth expectations in sales/revenue/volumes?

Strong revenue growth expected in FY '26 and beyond, with overall growth of over 30% anticipated. Letter of Intents (LOIs) contributing around INR 450-500 crores this year, expected to double compared to last year. Similar growth trajectory expected next year as many LOIs and contracts get commercialized and ramped up. Pharma segment revenue grew 3x year-on-year, expected to continue strong growth supported by new molecule launches. Performance materials segment projected to grow from double-digit contribution to 15-20% in the current year, reaching 20-25% in next 2-3 years. Continued strong p

Future growth expectations in earnings/operating earnings/profits/EPS?

Anupam Rasayan expects strong revenue growth of over 30% in FY '26 driven by all segments: agro, pharma, polymer, and personal care. Pharma segment revenue has shown 3x growth YoY, with continued ramp-up of new molecules launched in the last 18–24 months. Performance materials segment is expected to grow from double-digit contribution to 15-20% in FY '26 and 20-25% in the next 2-3 years. EBITDA margin for Q1 FY '26 stood at 26.3% consolidated, with standalone margin at 31%, indicating healthy profitability. The company aims to maintain EBITDA margins around 25-27% for incremental growth. Profi

Current/ Expected Orderbook/ Pending Orders?

Current order book stands at INR 14,646 crores, including recently signed LOIs with Japanese and U.S.-based multinational companies. LOIs largely cater to polymer (performance chemicals) and agrochemical segments. Expected order inflow for the current year is around INR 450-500 crores, with plans to double the LOI contribution compared to last year. Similar growth in LOI order book is expected next year as many contracts are commercializing and ramping up. Collaboration with a Japan-based fluorochemical conglomerate involves multiple niche molecules, mainly in specialty polymers, with

IN US

Sale is live|00:00:00left today

Anupam Rasayan India LtdQ2 FY25Chemicals & Petrochemicals

Anupam Rasayan India Ltd Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,266P/E: 91.1Market Cap: ₹15.7K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

1 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

→Strong revenue growth expected in FY '26 and beyond, with overall growth of over 30% anticipated.
→Letter of Intents (LOIs) contributing around INR 450-500 crores this year, expected to double compared to last year.
→Similar growth trajectory expected next year as many LOIs and contracts get commercialized and ramped up.
→Pharma segment revenue grew 3x year-on-year, expected to continue strong growth supported by new molecule launches.
→Performance materials segment projected to grow from double-digit contribution to 15-20% in the current year, reaching 20-25% in next 2-3 years.
→Continued strong performance in pharma, polymer, and agrochemical segments.
→Ongoing commercialization of molecules in specialty polymers and fluorochemicals with multinational collaborations expected to support sustained growth.

Margin guidance

Category 3

→Anupam Rasayan expects strong revenue growth of over 30% in FY '26 driven by all segments: agro, pharma, polymer, and personal care.
→Pharma segment revenue has shown 3x growth YoY, with continued ramp-up of new molecules launched in the last 18–24 months.
→Performance materials segment is expected to grow from double-digit contribution to 15-20% in FY '26 and 20-25% in the next 2-3 years.
→EBITDA margin for Q1 FY '26 stood at 26.3% consolidated, with standalone margin at 31%, indicating healthy profitability.
→The company aims to maintain EBITDA margins around 25-27% for incremental growth.
→Profit after tax margin was 10% for Q1 FY '26.
→Long-term focus on debt reduction and working capital optimization should strengthen financial health and support sustainable profit growth.
→Management expressed confidence in delivering sustained and profitable growth moving forward.

3 more insights locked — sign up free to unlock

Fundraise plans

→The company received INR 277.5 crores from a preferential issue in July 2025, of which INR 175 crores has already been used to repay term debt.
→Currently, the company is long-term net debt free on a net term debt basis.
→Debt-to-EBITDA ratio is less than 2, with management targeting to keep it below 2, aiming for around 1.5 or less.
→Working capital utilization is expected to improve, with inventory rationalization and no major capex planned, which should help reduce debt further.
→No explicit mention of new fundraising through debt or equity during the call beyond the preferential issue received in July 2025.
→Operating cash flows are expected to assist in ongoing debt reduction.

Order book

Yes

→Current order book stands at INR 14,646 crores, including recently signed LOIs with Japanese and U.S.-based multinational companies.
→LOIs largely cater to polymer (performance chemicals) and agrochemical segments.
→Expected order inflow for the current year is around INR 450-500 crores, with plans to double the LOI contribution compared to last year.
→Similar growth in LOI order book is expected next year as many contracts are commercializing and ramping up.
→Collaboration with a Japan-based fluorochemical conglomerate involves multiple niche molecules, mainly in specialty polymers, with commercialization ramping up next year.
→Order book alignment is strong across pharma, agrochemicals, polymers, and personal care segments, with pharma and polymer segments showing significant growth.

Capex plans

→All planned capex projects have been completed, with plants commissioned and fully operational.
→Two new plants have been commercialized, and trial runs are ongoing in one additional plant.
→No major capex is planned or necessitated in the near term.
→The company is focusing on leveraging existing manufacturing capacities to ramp up new molecule launches and orders.
→Emphasis is on optimizing working capital rather than incurring significant new capital investments in FY '26.

How does Anupam Rasayan India Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Anupam Rasayan India Ltd

Rev 2Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Anupam Rasayan India Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio